JP2000506125A5 - - Google Patents

Download PDF

Info

Publication number
JP2000506125A5
JP2000506125A5 JP1997529806A JP52980697A JP2000506125A5 JP 2000506125 A5 JP2000506125 A5 JP 2000506125A5 JP 1997529806 A JP1997529806 A JP 1997529806A JP 52980697 A JP52980697 A JP 52980697A JP 2000506125 A5 JP2000506125 A5 JP 2000506125A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997529806A
Other languages
English (en)
Japanese (ja)
Other versions
JP4184433B2 (ja
JP2000506125A (ja
Filing date
Publication date
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Priority claimed from DE19638313A external-priority patent/DE19638313C2/de
Priority claimed from DE19648687A external-priority patent/DE19648687A1/de
Application filed filed Critical
Priority claimed from PCT/EP1997/000828 external-priority patent/WO1997030721A1/de
Publication of JP2000506125A publication Critical patent/JP2000506125A/ja
Publication of JP2000506125A5 publication Critical patent/JP2000506125A5/ja
Application granted granted Critical
Publication of JP4184433B2 publication Critical patent/JP4184433B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP52980697A 1996-02-24 1997-02-21 免疫調節のための医薬組成物 Expired - Fee Related JP4184433B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE19607044.9 1996-02-24
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19638313.7 1996-09-19
DE19638313A DE19638313C2 (de) 1996-09-19 1996-09-19 Pharmazeutische Zusammensetzung für die Immunmodulation
DE19648687A DE19648687A1 (de) 1996-11-25 1996-11-25 Pharmazeutische Zusammensetzung für die Immunmodulation
DE19648687.4 1996-11-25
PCT/EP1997/000828 WO1997030721A1 (de) 1996-02-24 1997-02-21 Pharmazeutische zusammensetzung für die immunmodulation beruhend auf peptiden und adjuvantien

Publications (3)

Publication Number Publication Date
JP2000506125A JP2000506125A (ja) 2000-05-23
JP2000506125A5 true JP2000506125A5 (2) 2004-11-25
JP4184433B2 JP4184433B2 (ja) 2008-11-19

Family

ID=27215945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52980697A Expired - Fee Related JP4184433B2 (ja) 1996-02-24 1997-02-21 免疫調節のための医薬組成物

Country Status (34)

Country Link
US (1) US7105162B1 (2)
EP (1) EP0881906B2 (2)
JP (1) JP4184433B2 (2)
KR (1) KR100457647B1 (2)
CN (1) CN1177610C (2)
AR (1) AR005945A1 (2)
AT (1) ATE274350T1 (2)
AU (1) AU722264B2 (2)
BG (1) BG63682B1 (2)
BR (1) BR9707694A (2)
CA (1) CA2243559C (2)
CO (1) CO4600681A1 (2)
CZ (1) CZ295396B6 (2)
DE (1) DE59711873D1 (2)
DK (1) DK0881906T4 (2)
EE (1) EE04481B1 (2)
ES (1) ES2225951T5 (2)
HR (1) HRP970100B1 (2)
HU (1) HU224410B1 (2)
ID (1) ID16038A (2)
IL (1) IL125361A (2)
MY (1) MY119276A (2)
NO (1) NO983850L (2)
NZ (1) NZ332020A (2)
PE (1) PE55398A1 (2)
PL (1) PL189413B1 (2)
PT (1) PT881906E (2)
RO (1) RO119344B1 (2)
RS (1) RS50101B (2)
SI (1) SI0881906T2 (2)
SK (1) SK284582B6 (2)
TR (1) TR199801649T2 (2)
TW (1) TW585774B (2)
WO (1) WO1997030721A1 (2)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
WO1999043350A1 (en) * 1998-02-25 1999-09-02 Iomai Corporation Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by adp-ribosylating exotoxin
DE69837350T2 (de) * 1998-04-20 2007-11-29 Torrey Pines Institute For Molecular Studies, San Diego Topische immunostimulierung zur induzierung der migration der langerhanszellen
ES2572834T3 (es) * 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
DE19909503A1 (de) * 1999-03-04 2000-09-07 Boehringer Ingelheim Int Tumorassoziiertes Antigen
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AT409762B (de) * 2000-04-13 2002-11-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung von zytokin sekretierenden zellen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
KR20020014459A (ko) * 2000-08-18 2002-02-25 서진호 양이온성 아미노산이 부가된 융합단백질 및 이를 이용한생물공정의 개선방법
WO2002053184A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
EP1347775B1 (en) 2001-01-05 2016-11-30 Valneva Austria GmbH Uses for polycationic compounds as vaccine adjuvants
WO2002053185A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Anti-inflammatory use of polycationic compounds
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
CA2452909A1 (en) * 2001-12-07 2003-06-13 Intercell Ag Immunostimulatory oligodeoxynucleotides
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
CA2484941A1 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
EP2314603A3 (en) 2002-10-15 2011-05-18 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and futher uses thereof
EP1601770B1 (en) 2003-03-04 2009-09-02 Intercell AG Streptococcus pyogenes antigens
ES2562456T3 (es) 2003-03-24 2016-03-04 Valneva Austria Gmbh Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
EP1608756B1 (en) 2003-03-31 2009-11-18 Intercell AG Staphylococcus epidermidis antigens
EP2333114A1 (en) 2003-04-15 2011-06-15 Intercell AG S. pneumoniae antigens
EP1620460A2 (en) 2003-05-07 2006-02-01 Intercell AG Streptococcus agalactiae antigens i + ii
CN102304527A (zh) 2003-05-30 2012-01-04 英特塞尔股份公司 肠球菌抗原
CA2530062A1 (en) 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines
EP1987843A3 (en) 2004-03-12 2011-10-26 Intercell AG Method for solubilising peptide mixtures
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
EP1791858B1 (en) 2004-09-24 2010-04-21 Intercell AG Modified vp1-capsid protein of parvovirus b19
CA2583026A1 (en) * 2004-10-29 2006-05-04 Intercell Ag Hcv vaccines for chronic hcv patients
WO2006112477A1 (ja) * 2005-04-20 2006-10-26 Taiho Pharmaceutical Co., Ltd. アジュバントとしてのポリアミノ酸
EP1887084A1 (en) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
WO2008031133A2 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
JP2008174490A (ja) * 2007-01-18 2008-07-31 Nitto Denko Corp 抗原性ペプチドを主成分とする薬剤
EP2152731A2 (en) 2007-05-02 2010-02-17 Intercell AG Klebsiella antigens
KR100748265B1 (ko) * 2007-06-15 2007-08-10 (주)성문엔지니어링 공동주택에 배선된 전선의 합선방지구조
AU2008265218A1 (en) 2007-06-18 2008-12-24 Intercell Ag Chlamydia antigens
PL2173376T3 (pl) 2007-08-02 2015-08-31 Biondvax Pharmaceuticals Ltd Multimeryczne wieloepitopowe szczepionki przeciwko grypie
ES2703571T3 (es) * 2008-03-27 2019-03-11 Nestec Sa Métodos para aumentar la absorción de péptidos, peptidomiméticos y otros sustratos de proteína de transporte gastrointestinal
BRPI0922132A2 (pt) 2008-12-03 2018-10-23 Protea Vaccine Tech Ltd fragmentos glutamil trna sintetase (gts).
EP2405938A2 (en) 2009-02-13 2012-01-18 Intercell AG Nontypable haemophilus influenzae antigens
US8858958B2 (en) * 2009-08-27 2014-10-14 Novartis Ag Adjuvant comprising aluminum, oligonucleotide and polycation
CA2780274C (en) 2009-11-09 2018-06-26 Spotlight Technology Partners Llc Fragmented hydrogels
WO2011057131A1 (en) 2009-11-09 2011-05-12 Spotlight Technology Partners Llc Polysaccharide based hydrogels
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
RU2478399C2 (ru) * 2011-06-16 2013-04-10 Государственное научное учреждение Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных Российской академии сельскохозяйственных наук (ГНУ ВНИИБТЖ Россельхозакадемии) Способ получения специфического иммуномодулятора
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
US10537626B2 (en) 2014-10-07 2020-01-21 Cytlimic Inc. HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell
EP3294324A1 (en) 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
CN108368260B (zh) * 2015-12-16 2020-09-29 休伯特保健公司 含有角鲨烯的基于两亲性聚氨基酸聚合物的疫苗佐剂组合物
CN109072227A (zh) 2016-03-15 2018-12-21 组库创世纪株式会社 用于免疫治疗的监测和诊断及治疗剂的设计
JP2019517577A (ja) * 2016-05-27 2019-06-24 エトゥビクス コーポレーション ネオエピトープワクチン組成物及びその使用方法
AU2017342189B2 (en) 2016-10-11 2023-09-21 Nec Corporation Medicine
CN107469067B (zh) * 2017-09-05 2018-06-19 浙江大学 一种多肽及其改造体在制备免疫调节药物中的应用
KR20210005646A (ko) 2018-04-26 2021-01-14 아게누스 인코포레이티드 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
CN110870913A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗
CN110870912A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 亚甲蓝类染料作为疫苗佐剂的应用、包含该佐剂的疫苗及其应用
CN117860879A (zh) * 2024-01-10 2024-04-12 广州医科大学附属肿瘤医院 一种纳米疫苗递送系统及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1290141A (2) 1968-05-31 1972-09-20
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4728639A (en) * 1982-07-27 1988-03-01 University Of Tennessee Research Corporation Type-specific opsonic antibodies evoked with a synthetic peptide of streptococcal M protein conjugated to polylysine without adjuvant
US6022544A (en) * 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US4956273A (en) * 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
IL82841A (en) * 1986-06-13 1992-11-15 Oncogen Ligands and in vitro methods for augmenting b-cell proliferation
GB2220939B (en) * 1988-06-10 1992-02-26 Medical Res Council Peptide fragments of hiv and their use in vaccines and diagnosis
AU4525589A (en) * 1988-10-27 1990-05-14 Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
US5480967A (en) 1990-01-05 1996-01-02 United Biomedical, Inc. HIV-1 core protein fragments
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
DE69333434T2 (de) 1992-04-03 2005-03-03 The Regents Of The University Of California, Oakland Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
AU668772B2 (en) 1992-08-31 1996-05-16 Ludwig Institute For Cancer Research Isolated nonapeptide derived from mage-3 gene and presented by HLA-A1, and uses thereof
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5409703A (en) * 1993-06-24 1995-04-25 Carrington Laboratories, Inc. Dried hydrogel from hydrophilic-hygroscopic polymer
CZ3000U1 (cs) * 1993-07-12 1995-02-22 Kufudakis Alekos Farmaceutický prostředek pro imunomodulační a adjuvantní léčbu
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
UY24367A1 (es) † 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria

Similar Documents

Publication Publication Date Title
JP2000512098A5 (2)
JP2000506264A5 (2)
JP2000511629A5 (2)
JP2000507714A5 (2)
JP2000511733A5 (2)
JP2001506384A5 (2)
JP2001501842A5 (2)
JP2000507756A5 (2)
JP2000506650A5 (2)
JP2000504992A5 (2)
JP2000512498A5 (2)
JP2000510018A5 (2)
JP2000502472A5 (2)
JP2000504267A5 (2)
JP2000512231A5 (2)
JP2000503617A5 (2)
JP2000508468A5 (2)
JP2000508675A5 (2)
JP2000507952A5 (2)
JP2000507133A5 (2)
JP2000505356A5 (2)
JP2000506890A5 (2)
JP2000504045A5 (2)
JP2000503984A5 (2)
JP2000501569A5 (2)